Can old drugs learn new tricks?: Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

Jonathan Brett; Dilara Bahceci; Wendy Lipworth; Paul Liknaitzky; Ric O. Day; Anthony Rodgers

doi:10.1111/imj.16159

Can old drugs learn new tricks? Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

Jonathan Brett, Dilara Bahceci, Wendy Lipworth, Paul Liknaitzky, Ric O. Day, Anthony Rodgers

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

37 Downloads (Pure)

Abstract

With the increasing costs of drug development, repurposing of low-cost medicines for new indications has never been more important. However, there are multiple barriers to repurposing, particularly for off-patent medicines, and limited incentives for the pharmaceutical industry to sponsor registration and public subsidy listing. Here, we explore these barriers and their consequences and provide examples of successful repurposing strategies.

Original language	English
Pages (from-to)	1284-1287
Number of pages	4
Journal	Internal Medicine Journal
Volume	53
Issue number	7
DOIs	https://doi.org/10.1111/imj.16159
Publication status	Published - Jul 2023

Bibliographical note

Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

repurposing
generic
medicine
off-label
off-patent

Access to Document

10.1111/imj.16159

Publisher version (open access)Final published version, 382 KBLicence: CC BY

Cite this

@article{d613fea14c46466ca1321ce95f842c57,

title = "Can old drugs learn new tricks?: Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications",

abstract = "With the increasing costs of drug development, repurposing of low-cost medicines for new indications has never been more important. However, there are multiple barriers to repurposing, particularly for off-patent medicines, and limited incentives for the pharmaceutical industry to sponsor registration and public subsidy listing. Here, we explore these barriers and their consequences and provide examples of successful repurposing strategies.",

keywords = "repurposing, generic, medicine, off-label, off-patent",

author = "Jonathan Brett and Dilara Bahceci and Wendy Lipworth and Paul Liknaitzky and Day, \{Ric O.\} and Anthony Rodgers",

note = "Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2023",

month = jul,

doi = "10.1111/imj.16159",

language = "English",

volume = "53",

pages = "1284--1287",

journal = "Internal Medicine Journal",

issn = "1444-0903",

publisher = "John Wiley \& Sons",

number = "7",

}

TY - JOUR

T1 - Can old drugs learn new tricks?

T2 - Achieving registration and public subsidy listing for off-patent medicines with novel therapeutic applications

AU - Brett, Jonathan

AU - Bahceci, Dilara

AU - Lipworth, Wendy

AU - Liknaitzky, Paul

AU - Day, Ric O.

AU - Rodgers, Anthony

N1 - Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2023/7

Y1 - 2023/7

N2 - With the increasing costs of drug development, repurposing of low-cost medicines for new indications has never been more important. However, there are multiple barriers to repurposing, particularly for off-patent medicines, and limited incentives for the pharmaceutical industry to sponsor registration and public subsidy listing. Here, we explore these barriers and their consequences and provide examples of successful repurposing strategies.

AB - With the increasing costs of drug development, repurposing of low-cost medicines for new indications has never been more important. However, there are multiple barriers to repurposing, particularly for off-patent medicines, and limited incentives for the pharmaceutical industry to sponsor registration and public subsidy listing. Here, we explore these barriers and their consequences and provide examples of successful repurposing strategies.

KW - repurposing

KW - generic

KW - medicine

KW - off-label

KW - off-patent

UR - https://www.scopus.com/pages/publications/85164499602

U2 - 10.1111/imj.16159

DO - 10.1111/imj.16159

M3 - Article

C2 - 37409815

SN - 1444-0903

VL - 53

SP - 1284

EP - 1287

JO - Internal Medicine Journal

JF - Internal Medicine Journal

IS - 7

ER -